To decrease the incidence of hospital infections caused by meticillin-resistant Staphylococcus aureus (MRSA), an educational intervention study was performed in which the use of intravenous ciprofloxacin and third-generation cephalosporins was discouraged. The effect was assessed by observing the MRSA bacteraemia rate both within the hospital and the intensive care unit for 18 months before, and 16 months after, the two-month intervention programme. MRSA bacteraemia rate throughout the hospital was reduced by 62.9% (P<0.001) by the end of the study and MRSA colonisation rate was reduced by 38.4% (not significant). There was no concomitant decrease in episodes of bacteraemia caused by meticillin-susceptible Staphylococcus aureus (MSSA) during the study period. There was a fall in hospital dispensing of both ciprofloxacin (80.4%) and third-generation cephalosporins (75.2%). The overall incidence of MRSA bloodstream infections within critical care was reduced (4.200 vs 0.272 per 1000 occupied bed-days) but this was not significant.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jhin.2008.04.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant Infections: A Multicenter Cohort Study.
Pharmaceuticals (Basel)
January 2025
Department of Clinical Pharmacy, College of Pharmacy, University of Ha'il, P.O. Box 6166, Hail 81442, Saudi Arabia.
To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) infections. This is a multicenter, retrospective cohort study conducted in the period between 2017 and 2023 at five institutions for patients who received either CAZ-AVI or colistin-based regimens for treating MDR infections. Outcomes were compared using multivariate logistic regression analysis.
View Article and Find Full Text PDFComparative Analysis of Clinical Characteristics and Antimicrobial Resistance Between and Other Species.
Pathogens
January 2025
Division of Infectious Diseases, Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea.
species are major pathogens responsible for hospital-acquired infections. This study aimed to compare the clinical characteristics, outcomes, and antimicrobial resistance between (AB) and non- (NBA) species. In this retrospective cohort study, we analyzed data from adult patients (aged 18 or older) with bacteremia treated at two tertiary hospitals from July 2020 to November 2023.
View Article and Find Full Text PDFBloodstream Infections in Critical Care Units in England, April 2017 to March 2023: Results from the First Six Years of a National Surveillance Programme.
Microorganisms
January 2025
UK Health Security Agency, London E14 4PU, UK.
Background: Patients in critical care units (CCUs) are at an increased risk of bloodstream infections (BSIs), which can be associated with central vascular catheters (CVCs). This study describes BSIs, CVC-BSIs, organism distribution, percentage of antimicrobial resistant (AMR) organisms, and case fatality rates (CFRs) over the first six years of a voluntary national CCU surveillance programme in England.
Methods: Surveillance data on BSIs, CVCs, and bed-days between 04/2017 and 03/2023 for adult CCUs were linked to mortality and AMR data, and crude rates were calculated.
Identification of the Skip Phenomenon Among Patients With Infective Endocarditis: A Retrospective Review.
Open Forum Infect Dis
January 2025
Division of Public Health, Infectious Disease, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
The skip phenomenon (SP) is a pattern where blood cultures are intermittently positive before final clearance. We report that one-third of patients with infective endocarditis experienced the SP. Patients with the SP experienced both a longer duration of bacteremia and hospital stay, with a higher 1-year mortality rate.
View Article and Find Full Text PDFThe Outcomes of Pediatric, Adolescent, and Young Adult Oncology Patients With Non-neutropenic Fever: A Scoping Review of the Literature.
Curr Pediatr Rev
January 2025
University Medical Center of Saarland, Department of Pediatric Hematology and Oncology, Kirrberger Straße, Building 9, 66421, Homburg/Saar, Germany.
Background: There are established and well-followed guidelines for pediatric oncology patients who have neutropenic fever. However, there are no explicit criteria for this patient group, and over 50% of pediatric oncology patients with fever do not present with neutropenia.
Objective: In this scoping review, we have explored the outcomes of non-neutropenic fever in pediatric, adolescent, and young adult patients with cancer-directed treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!